About Type 2 Diabetes

Diabetes, often referred to as diabetes mellitus, is a metabolic disease in which the patients' blood glucose levels remains high. Depending on the cause of development of diabetes, it can be divided into three types:
• Type 1 diabetes (or insulin-dependent diabetes mellitus): In this condition, the pancreas do not produce the required amount of insulin, leading to high blood glucose levels.
• Type 2 diabetes (non-insulin dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it, increasing the glucose levels in the body.
• Gestational diabetes: This condition occurs in pregnant women without any prior history of diabetes
Type 2 diabetes, also known as adult-onset diabetes, is a result of the body's inability to produce enough insulin or insulin resistance or both. It is managed by providing symptomatic relief and improving the quality of life. Type 2 diabetes accounts for nearly 90%-95% of the total number of diabetes cases worldwide and is primarily diagnosed in the middle-aged and old age groups, i.e., between the ages of 30 and 75 years. However, it can occur even during childhood. The risks of type 2 diabetes include high blood pressure, advancing age, obesity, history of gestational diabetes, family history of diabetes, poor nutrition during pregnancy, physical inactivity, and impaired glucose tolerance.

Technavio’s analysts forecast the global type 2 diabetes drugs market to grow at a CAGR of 7.28% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global type 2 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat type 2 diabetes.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Type 2 Diabetes Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• AstraZeneca plc
• Eli Lilly and Company
• Merck & Co. Inc.
• Novo Nordisk A/S
• Sanofi SA

Other prominent vendors
• Adocia
• Akros Pharma
• Amgen
• Astellas Pharma
• Biocon
• Boehringer Ingelheim
• Chipscreen Biosciences
• ConjuChem
• CymaBay Therapeutics
• Daiichi Sankyo
• DiaMedica
• Diasome Pharmaceuticals
• Dong-A ST
• Elcelyx Therapeutics
• Exsulin
• Generex
• Genfit
• Hanmi
• Hua Medicine
• InteKrin Therapeutics
• Ionis Pharmaceuticals
• Janssen Pharmaceuticals
• Japan Tobacco
• Kadmon
• KinDex Pharmaceuticals
• Kissei
• Kotobuki Pharmaceutical
• Lexicon Pharmaceuticals
• Ligand
• MannKind
• MedImmune
• Melior Pharmaceuticals
• Metabolic Solutions Development Company
• Mitsubishi Tanabe Pharma
• Novartis
• NGM Bio
• NuSirt Biopharma
• Oramed
• Peptron
• Pfizer
• PhaseBio
• Poxel
• Sanwa Kagaku Kenkyusho
• Sirona Biochem
• Takeda
• Theracos
• Theratechnologies
• Transition Therapeutics
• VeroScience
• vTv Therapeutics
• XBiotech

Market driver
• Rising prevalence of diabetes
• For a full, detailed list, view our report

Market challenge
• Low diagnosis rate
• For a full, detailed list, view our report

Market trend
• Increase in awareness of diabetes
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.